Loading...
Loading...
Browse all stories on DeepNewz
VisitWill Remi Barbier step down as CEO of Cassava Sciences by September 26, 2025?
Yes • 50%
No • 50%
Public announcements from Cassava Sciences, news reports
Cassava Sciences Settles with SEC for $40M Over Falsified Alzheimer's Drug Data; Barbier and Burns Named
Sep 26, 2024, 09:57 PM
Cassava Sciences, Inc. ($SAVA) and its executives have settled with the Securities and Exchange Commission (SEC) for $40 million over allegations of falsifying phase 2 trial data for their Alzheimer's drug, simufilam. The SEC charges revealed that the placebo outperformed both doses of the drug, and the original data showed no measurable cognitive improvement in patients' episodic memory. CEO Rick Barry admitted discrepancies between Quanterix data and Wang's CUNY data. The company faces significant legal challenges and investor skepticism, with its current cash position at approximately $200 million and a burn rate of $80 million per year. Remi Barbier and Lindsay Burns were also named in the SEC charges.
View original story
Yes • 50%
No • 50%
Remi Barbier joins another biotech company • 25%
Remi Barbier retires • 25%
Remi Barbier starts a new company • 25%
Remi Barbier takes a non-executive role • 25%
Cassava Sciences wins the lawsuits • 25%
Cassava Sciences settles the lawsuits • 25%
Cassava Sciences loses the lawsuits • 25%
Lawsuits are dismissed • 25%
CEO replaced • 25%
CFO replaced • 25%
Both CEO and CFO replaced • 25%
No changes in executive leadership • 25%
Yes • 50%
No • 50%
Above $200 million • 25%
Below $50 million • 25%
Between $50 million and $100 million • 25%
Between $100 million and $200 million • 25%
Case dismissed • 25%
Favorable ruling for Cassava Sciences • 25%
Unfavorable ruling for Cassava Sciences • 25%
Settlement • 25%